Hims & Hers Health (HIMS) Cash & Current Investments (2019 - 2026)
Hims & Hers Health (HIMS) reported Cash & Current Investments of $750.9 million for Q1 2026, up 132.71% on a YoY basis from $322.7 million in Q1 2025, and up 30.02% sequentially from $577.5 million in Q4 2025.
Hims & Hers Health (HIMS) Cash & Current Investments (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Cash & Current Investments data on file, last reported at $750.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 132.71% year-over-year to $750.9 million; the trailing twelve-month figure through Mar 2026 stood at $750.9 million (up 132.71% YoY), and the FY2025 full-year result was $577.5 million, up 92.34% from the prior year.
- Cash & Current Investments improved to $750.9 million in Q1 2026, from $577.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $1.1 billion in Q2 2025 to a low of $179.6 million in Q4 2022.
- A 5-year average of $352.8 million and a median of $221.0 million in 2023 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments tumbled 38.56% in 2022 and soared 403.59% in 2025, its largest moves.
- Tracing HIMS's Cash & Current Investments over 5 years: stood at $179.6 million in 2022, then increased by 23.02% to $221.0 million in 2023, then surged by 35.87% to $300.3 million in 2024, then soared by 92.34% to $577.5 million in 2025, then surged by 30.02% to $750.9 million in 2026.
- Business Quant data shows HIMS's Cash & Current Investments at $750.9 million in Q1 2026, $577.5 million in Q4 2025, and $629.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 750.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 750.88 Mn |
| Dec 31, 2025 | 577.49 Mn |
| Sep 30, 2025 | 629.74 Mn |
| Jun 30, 2025 | 1.14 Bn |
| Mar 31, 2025 | 322.67 Mn |
| Dec 31, 2024 | 300.25 Mn |
| Sep 30, 2024 | 254.07 Mn |
| Jun 30, 2024 | 227.29 Mn |
| Mar 31, 2024 | 203.59 Mn |
| Dec 31, 2023 | 220.98 Mn |
| Sep 30, 2023 | 212.50 Mn |
| Jun 30, 2023 | 193.14 Mn |
| Mar 31, 2023 | 184.39 Mn |
| Dec 31, 2022 | 179.63 Mn |
| Sep 30, 2022 | 198.39 Mn |
| Jun 30, 2022 | 194.98 Mn |
| Mar 31, 2022 | 203.05 Mn |
| Dec 31, 2021 | 247.27 Mn |
| Sep 30, 2021 | 252.43 Mn |
| Jun 30, 2021 | 317.32 Mn |